• Login
    View Item 
    •   Home
    • iBEST Institute of Biomedical and Environmental Science and Technology - to April 2016
    • Cell and Cryobiology Research Group
    • View Item
    •   Home
    • iBEST Institute of Biomedical and Environmental Science and Technology - to April 2016
    • Cell and Cryobiology Research Group
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UOBREPCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsPublisherJournalDepartmentThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsPublisherJournalDepartment

    My Account

    LoginRegister

    About

    AboutLearning ResourcesResearch Graduate SchoolResearch InstitutesUniversity Website

    Statistics

    Display statistics

    Pharmaco(epi)genomics in ovarian cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Paige, Adam J.W.
    Brown, Robert
    Affiliation
    Imperial College
    Issue Date
    2008-12
    
    Metadata
    Show full item record
    Abstract
    Ovarian cancer shows considerable variability in its chemoresponse, however, the prospect of individualized medicine holds high hopes for improving patient survival. The influence of interindividual genomic polymorphisms on drug response (pharmacogenomics) is well established, and a variety of candidate loci in ovarian tumors have been identified, including ERCC1, ABCB1 and p53 variants. Recently pharmacoepigenomic modulators of key genes and pathways, such as promoter methylation (MLH1 and BRCA1 genes) and microRNA regulation (PTEN/AKT and NF-kappaB pathways) have been implicated in ovarian cancer chemoresponse. Epigenomic studies have until now mainly focused on tumor-specific changes, although germ-line epigenetic change may also be of importance. However, assessing the relevance of these potential pharmaco(epi)genomic biomarkers in clinical trials requires well powered studies in homogeneous populations, with independent validation sets, to distinguish real associations from false-positives. In addition, the selection of one gene or locus as having sufficient phenotypic effect to impact on clinical outcome may be an oversimplification. Integrated approaches that identify stable pharmacogenomic and epigenomic patterns and their relationship with expression patterns and gene function will be increasingly necessary.
    Citation
    Paige, A.J.W., Brown, R. (2008) 'Pharmaco(epi)genomics in ovarian cancer' Pharmacogenomics 9 (12):1825-1834
    Publisher
    Future Medicine
    Journal
    Pharmacogenomics
    URI
    http://hdl.handle.net/10547/228927
    DOI
    10.2217/14622416.9.12.1825
    PubMed ID
    19072641
    Additional Links
    https://www.futuremedicine.com/doi/abs/10.2217/14622416.9.12.1825?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=pgs
    Type
    Article
    Language
    en
    ISSN
    1744-8042
    ae974a485f413a2113503eed53cd6c53
    10.2217/14622416.9.12.1825
    Scopus Count
    Collections
    Cell and Cryobiology Research Group

    entitlement

    Related articles

    • Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
    • Authors: Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R
    • Issue date: 2007 Oct 10
    • BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
    • Authors: Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G
    • Issue date: 2012 Jul 20
    • An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    • Authors: Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM
    • Issue date: 2007 Feb 10
    • Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma.
    • Authors: Chetty C, Rao JS, Lakka SS
    • Issue date: 2011 Apr
    • Specific copy number alterations associated with docetaxel/carboplatin response in ovarian carcinomas.
    • Authors: Osterberg L, Levan K, Partheen K, Delle U, Olsson B, Sundfeldt K, Horvath G
    • Issue date: 2010 Nov
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.